Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics Inc. released its financial results and a corporate update for the third quarter ended September 30, 2026, in conjunction with its 10-Q filing.
Stocks · News reference
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Foghorn Therapeutics Inc. (FHTX)
Filed: 2026-11-09 AccNo: 0001628280-26-071871 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
Foghorn Therapeutics announced that its management team will participate in three investor conferences throughout November 2026.
Foghorn Therapeutics shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
TD Cowen Downgrades Foghorn Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Hold.
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5